Next Article in Journal
Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient
Previous Article in Journal
Antimicrobial Peptides
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2014, 7(1), 1-17; doi:10.3390/ph7010001

A New Phenylpyrazoleanilide, Y-320, Inhibits Interleukin 17 Production and Ameliorates Collagen-Induced Arthritis in Mice and Cynomolgus Monkeys

1
Process Chemistry Research Laboratories, CMC Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi 532-8505, Japan
2
Medicinal Chemistry Research Laboratories I, Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033, Japan
3
Pharmacology Research Laboratories I, Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033, Japan
4
Advanced Medical Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033, Japan
*
Author to whom correspondence should be addressed.
Received: 5 November 2013 / Revised: 16 December 2013 / Accepted: 18 December 2013 / Published: 23 December 2013
View Full-Text   |   Download PDF [414 KB, uploaded 23 December 2013]   |  

Abstract

Interleukin (IL)-15 and IL-17 are thought to play an important role in the pathogenesis of rheumatoid arthritis (RA) because both pro-inflammatory cytokines are found in synovial fluid of RA patients. In this study, we examined the pharmacological profiles of Y-320, a new phenylpyrazoleanilide immunomodulator. Y-320 inhibited IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM. Oral administration of Y-320 (0.3 to 3 mg/kg) significantly inhibited the development and progression of arthritis and joint destruction with reduction of IL-17 mRNA expression in arthritic joints of type II collagen-induced arthritis (CIA) in DBA/1J mice. Y-320 in combination with anti-murine tumor necrosis factor-α monoclonal antibody showed a synergistic effect on mouse CIA. Moreover, therapeutic treatment with Y-320 (0.3 and 1 mg/kg orally) ameliorated CIA in cynomolgus monkeys. Our results suggest that Y-320, an orally active inhibitor for IL-17 production, provides a useful therapy for RA. View Full-Text
Keywords: interleukin 15 (IL-15); interleukin 17 (IL-17); phenylpyrazoleanilide; Y-320; immunomodulator; collagen-induced arthritis (CIA); rheumatoid arthritis (RA) interleukin 15 (IL-15); interleukin 17 (IL-17); phenylpyrazoleanilide; Y-320; immunomodulator; collagen-induced arthritis (CIA); rheumatoid arthritis (RA)
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Ushio, H.; Ishibuchi, S.; Oshita, K.; Seki, N.; Kataoka, H.; Sugahara, K.; Adachi, K.; Chiba, K. A New Phenylpyrazoleanilide, Y-320, Inhibits Interleukin 17 Production and Ameliorates Collagen-Induced Arthritis in Mice and Cynomolgus Monkeys. Pharmaceuticals 2014, 7, 1-17.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top